In this issue:
ICON8: no survival benefit to front-line dose-dense chemotherapy
Delay in adjuvant chemotherapy administration reduces survival
No survival benefit to single-agent taxane maintenance
ATHENA: PARP inhibition maintenance extends PFS in advanced disease
Navicixizumab/paclitaxel has anti-tumour activity in platinum-resistant disease
TRACKBACK reports cancer prevention potential of retrospective genetic testing
Survival not affected by Olaparib maintenance dose alterations
Adavosertib combinations show promise in platinum-resistant disease
BRCA status in advanced disease according to CRS
End-of-life care for patients with advanced ovarian cancer in the Netherlands
Please login below to download this issue (PDF)